Tevogen Bio’s (TVGN) “Buy” Rating Reiterated at D. Boral Capital

by · The Cerbat Gem

D. Boral Capital reaffirmed their buy rating on shares of Tevogen Bio (NASDAQ:TVGN – Free Report) in a research note released on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $10.00 price target on the stock.

Tevogen Bio Stock Performance

Shares of Tevogen Bio stock opened at $1.11 on Tuesday. The firm’s 50-day simple moving average is $1.36 and its 200-day simple moving average is $1.17. Tevogen Bio has a twelve month low of $0.26 and a twelve month high of $6.53.

Insider Activity

In other news, insider Neal Flomenberg sold 88,519 shares of Tevogen Bio stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $1.10, for a total transaction of $97,370.90. Following the sale, the insider now directly owns 4,040,485 shares in the company, valued at approximately $4,444,533.50. The trade was a 2.14 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders have sold 173,542 shares of company stock worth $192,827. Corporate insiders own 56.60% of the company’s stock.

Hedge Funds Weigh In On Tevogen Bio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TVGN. HGC Investment Management Inc. acquired a new position in Tevogen Bio in the third quarter valued at about $82,000. China Universal Asset Management Co. Ltd. acquired a new position in Tevogen Bio in the fourth quarter valued at about $38,000. JPMorgan Chase & Co. boosted its position in Tevogen Bio by 74.2% in the fourth quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock valued at $40,000 after buying an additional 16,695 shares in the last quarter. Geode Capital Management LLC boosted its position in Tevogen Bio by 31.2% in the fourth quarter. Geode Capital Management LLC now owns 451,851 shares of the company’s stock valued at $465,000 after buying an additional 107,566 shares in the last quarter. Finally, Barclays PLC boosted its position in Tevogen Bio by 39.2% in the fourth quarter. Barclays PLC now owns 45,600 shares of the company’s stock valued at $48,000 after buying an additional 12,847 shares in the last quarter.

Tevogen Bio Company Profile

(Get Free Report)

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.

Featured Stories